Overview
Compare with VASO Corp, BIOLIFE SOLUTIONS INC or ViewRay, or pick any stock.
- TickerCBLL on Nasdaq2
- IndustryElectromedical & Electrotherapeutic Apparatus2
- HeadquartersSunnyvale, United States2
- Incorporated inDE3
- Business address360 N. Pastoria Avenue, Sunnyvale, Ca 940853
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
- Legal formCorporation2
- LEI254900XFP5492GQXKO052
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 55952442
See how the biggest companies compare on our leaderboards
A seizure is an abnormal burst of uncontrolled electrical activity in the brain which, if left untreated, can result in permanent disability or death. Seizures are often associated with epilepsy, a chronic condition that causes recurring seizures throughout an individual’s life. However, seizures in the acute care setting are also commonly triggered by serious conditions such as brain tumors, traumatic brain injury, stroke, cardiac arrest, and sepsis, among others. In contrast to epileptic seizures which are short in duration and typically involve convulsions, seizures occurring in the acute care setting tend to be longer in duration and are most often non-convulsive, meaning they lack the physical symptoms that are often used to identify seizure activity, which makes empirical diagnosis extremely challenging. This creates a significant unmet need, and it is estimated that up to 92% of a…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
87.9%Gross margin5
-65.6%Operating margin5
-60.0%Net margin5
36.1%Revenue growth, 20255
-34.4%Return on equity5
-$41.6MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 76% of the revenue Ceribell, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $50.1M | $67.3M |
| Subscription | $15.4M | $21.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue12¢$10.8M
- Research and development21¢$19.1M
- Other costs66¢$59.1M
Out of $89.1M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $89.1M | $65.4M |
| Total cost of revenue | $10.8M | $8.7M |
| Gross profit | $78.3M | $56.8M |
| Research and development | $19.1M | $13.6M |
| Sales and marketing | $73.1M | $49.1M |
| General and administrative | $44.5M | $33.8M |
| Total operating expenses | $136.7M | $96.5M |
| Loss from operations | -$58.4M | -$39.7M |
| Interest expense | -$1.9M | -$2.0M |
| Change in fair value of warrant liability | $0 | -$1.5M |
| Other income, net | $6.9M | $2.7M |
| Loss, before provision for income taxes | -$53.4M | -$40.5M |
| Provision for income tax expense | $0 | $0 |
| Net loss | -$53.4M | -$40.5M |
| Basic | -$1.46 | -$3.39 |
| Diluted | -$1.46 | -$3.39 |
| Basic | 36.5M shares | 11.9M shares |
| Diluted | 36.5M shares | 11.9M shares |
| Unrealized gain on marketable securities | $159.0K | $0 |
| Comprehensive loss | -$53.3M | -$40.5M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $40.5M | $194.4M | |
| Marketable securities | $118.8M | ||
| Accounts receivable, net | $15.1M | $10.9M | |
| Inventory | $7.3M | $6.9M | |
| Contract costs, current | $2.2M | $1.8M | |
| Prepaid expenses and other current assets | $2.9M | $3.2M | |
| Total current assets | $186.7M | $217.3M | |
| Property and equipment, net | $2.0M | $2.3M | |
| Operating lease right-of-use assets | $2.3M | $2.1M | |
| Contract costs, long-term | $1.8M | $1.5M | |
| Other non-current assets | $2.9M | $2.2M | |
| Total assets | $195.8M | $225.4M | |
| Accounts payable | $2.8M | $1.1M | |
| Accrued liabilities | $14.3M | $10.1M | |
| Contract liabilities, current | $101.0K | $97.0K | |
| Operating lease liability, current | $1.1M | $1.1M | |
| Other current liabilities | $818.0K | $609.0K | |
| Total current liabilities | $19.2M | $13.0M | |
| Notes payable, long-term | $19.8M | $19.6M | |
| Contract liabilities, long-term | $0 | $30.0K | |
| Other liabilities, long-term | $106.0K | $356.0K | |
| Operating lease liability, long-term | $1.4M | $1.3M | |
| Total long-term liabilities | $21.3M | $21.3M | |
| Total liabilities | $40.5M | $34.2M | |
| Common stock, $0.001 par value; Authorized shares: 500,000,000 as of December 31, 2025 and December 31, 2024, respectively Issued and outstanding shares: 37,485,124 and 35,850,60 as of December 31, 2025 and December 31, 2024, respectively. | $38.0K | $36.0K | |
| Additional paid-in capital | $375.5M | $358.1M | |
| Accumulated other comprehensive income | $159.0K | ||
| Accumulated deficit | -$220.4M | -$166.9M | |
| Total stockholders' deficit | $155.3M | $191.2M | -$112.3M |
| Total liabilities and stockholders' equity | $195.8M | $225.4M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 37.5M shares | 35.9M shares | |
| Common stock, shares outstanding | 37.5M shares | 35.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $40.5M | $194.4M | |
| Marketable securities | $118.8M | ||
| Accounts receivable, net | $15.1M | $10.9M | |
| Inventory | $7.3M | $6.9M | |
| Contract costs, current | $2.2M | $1.8M | |
| Prepaid expenses and other current assets | $2.9M | $3.2M | |
| Total current assets | $186.7M | $217.3M | |
| Property and equipment, net | $2.0M | $2.3M | |
| Operating lease right-of-use assets | $2.3M | $2.1M | |
| Contract costs, long-term | $1.8M | $1.5M | |
| Other non-current assets | $2.9M | $2.2M | |
| Total assets | $195.8M | $225.4M | |
| Accounts payable | $2.8M | $1.1M | |
| Accrued liabilities | $14.3M | $10.1M | |
| Contract liabilities, current | $101.0K | $97.0K | |
| Operating lease liability, current | $1.1M | $1.1M | |
| Other current liabilities | $818.0K | $609.0K | |
| Total current liabilities | $19.2M | $13.0M | |
| Notes payable, long-term | $19.8M | $19.6M | |
| Contract liabilities, long-term | $0 | $30.0K | |
| Other liabilities, long-term | $106.0K | $356.0K | |
| Operating lease liability, long-term | $1.4M | $1.3M | |
| Total long-term liabilities | $21.3M | $21.3M | |
| Total liabilities | $40.5M | $34.2M | |
| Common stock, $0.001 par value; Authorized shares: 500,000,000 as of December 31, 2025 and December 31, 2024, respectively Issued and outstanding shares: 37,485,124 and 35,850,60 as of December 31, 2025 and December 31, 2024, respectively. | $38.0K | $36.0K | |
| Additional paid-in capital | $375.5M | $358.1M | |
| Accumulated other comprehensive income | $159.0K | ||
| Accumulated deficit | -$220.4M | -$166.9M | |
| Total stockholders' deficit | $155.3M | $191.2M | -$112.3M |
| Total liabilities and stockholders' equity | $195.8M | $225.4M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 37.5M shares | 35.9M shares | |
| Common stock, shares outstanding | 37.5M shares | 35.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$53.4M | -$40.5M |
| Depreciation and amortization expense | $1.3M | $1.1M |
| Noncash lease expense | -$101.0K | $59.0K |
| Stock-based compensation expense | $12.2M | $5.4M |
| Amortization of debt discount and accretion of premium on term loans | $415.0K | $382.0K |
| Accretion (amortization) of discount and premium on marketable securities | -$2.0M | $0 |
| Change in fair value of warrant liability | $0 | $1.5M |
| Loss on disposal of property and equipment and recorders | $104.0K | $95.0K |
| Accounts receivable, net | -$4.2M | -$2.9M |
| Inventory | -$351.0K | -$1.1M |
| Prepaid expenses and other current assets | $345.0K | -$1.1M |
| Contract costs | -$713.0K | -$591.0K |
| Other non-current asset | -$415.0K | -$65.0K |
| Accounts payable | $1.7M | $250.0K |
| Accrued liabilities and other current liabilities | $4.2M | $2.5M |
| Contract liabilities | -$26.0K | -$123.0K |
| Net cash used in operating activities | -$40.8M | -$35.0M |
| Purchases of recorder components and recorders | -$755.0K | -$258.0K |
| Purchases of property and equipment | -$767.0K | -$1.3M |
| Purchases of marketable securities | -$210.8M | $0 |
| Proceeds from maturities of marketable securities | $94.2M | $0 |
| Net cash used in investing activities | -$118.1M | -$1.6M |
| Proceeds related to employee stock plans | $5.4M | $1.1M |
| Taxes withheld and paid related to settlement or vesting of equity awards | -$236.0K | $0 |
| Proceeds from debt issuance | $0 | $7.9M |
| Debt issuance cost | -$150.0K | -$304.0K |
| Payment of deferred IPO offering costs | $0 | -$5.0M |
| Proceeds from IPO, net of commissions | $0 | $192.8M |
| Net cash provided by financing activities | $5.1M | $196.5M |
| Net increase (decrease) in cash and cash equivalents | -$153.9M | $159.9M |
| Cash paid for interest | $1.9M | $2.0M |
| Right-of-use asset obtained in exchange for operating lease obligation | $1.1M | $778.0K |
| Property and equipment included in accounts payable and accrued expenses | $63.0K | $99.0K |
| Recorder components included in accounts payable and accrued expenses | $67.0K | $69.0K |
| Conversion of redeemable convertible preferred stock into common stock on completion of IPO | $0 | $147.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Ceribell, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Ceribell, Inc.
- TPG GP A, LLC Filed SCHEDULE 13G/A on Ceribell, Inc., latest Aug 14, 2026 (2 filings since Feb 13, 2025)
- FMR LLC Filed SCHEDULE 13G/A on Ceribell, Inc., latest Aug 6, 2026 (5 filings since Nov 7, 2024)
- BlackRock Filed SCHEDULE 13G on Ceribell, Inc., latest Jul 27, 2026
- Global Value Investment Portfolio Management Pte Ltd Filed SCHEDULE 13G/A on Ceribell, Inc., latest May 14, 2026 (2 filings since Feb 20, 2025)
- Xingjuan Chao Filed SCHEDULE 13G/A on Ceribell, Inc., latest May 12, 2026 (2 filings since Feb 12, 2025)
- ABG Management Ltd. Filed SCHEDULE 13G/A on Ceribell, Inc., latest Dec 11, 2025 (2 filings since May 2, 2025)
- Red Tree GP, LLC Filed SCHEDULE 13G on Ceribell, Inc., latest Feb 14, 2025
- Josef Parvizi Filed SCHEDULE 13G on Ceribell, Inc., latest Feb 12, 2025
- Longitude Capital Partners IV, LLC Filed SC 13D on Ceribell, Inc., latest Oct 22, 2024
- Ceribell, Inc. Sunnyvale, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Ceribell, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $4.7M5 Dec 31, 2025 | $4.0M5 Dec 31, 2024 | +18.3% |
| Accumulated depreciation | $2.7M5 Dec 31, 2025 | $1.7M5 Dec 31, 2024 | +59.9% |
| Property and equipment, net | $2.0M5 Dec 31, 2025 | $2.3M5 Dec 31, 2024 | −12.2% |
| Operating-lease assets (leased space) | $2.3M5 Dec 31, 2025 | $2.1M5 Dec 31, 2024 | +7.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $40.5M5 Dec 31, 2025 | $194.4M5 Dec 31, 2024 | −79.2% |
| Marketable securities, current | $118.8M5 Dec 31, 2025 | ||
| Debt securities available for sale | $118.8M5 Dec 31, 2025 |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $7.3M5 Dec 31, 2025 | $6.9M5 Dec 31, 2024 | +5.1% |
| Raw materials | $5.0M5 Dec 31, 2025 | $4.1M5 Dec 31, 2024 | +21.8% |
| Finished goods | $2.3M5 Dec 31, 2025 | $2.8M5 Dec 31, 2024 | −19.0% |
Properties, in its own words
Our corporate headquarters is in Sunnyvale, California, where we lease a 15,600 square foot facility pursuant to a lease agreement which commenced on November 1, 2021. To support our growth, the Company entered into an operating lease agreement for a 11,600 square foot facility for additional office and warehouse space in Sunnyvale, California in May 2024. The lease commenced when the Company obtained early use of the property beginning on June 1, 2024. On December 11, 2025, the Company amended both leases to extend the terms through January 31, 2028.
Our existing facility will continue to support our research and development, finance, marketing, and administrative teams. We believe that our existing and new facilities are adequate to support our expansion through the end of the facilities’ lease periods. We believe that suitable additional or alternative space would be available in the future as required on commercially reasonable terms.
Item 2 of the 10-K filed Feb 24, 2026.4
Leadership
Who has led Ceribell, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerXingjuan Chao Oct 10, 2024 to now9
- PresidentXingjuan Chao Oct 10, 2024 to now9
- Chief financial officerScott Blumberg Oct 10, 2024 to now10
Board members and other officers (13)
- Chief Revenue OfficerJoseph S. Manni Apr 1, 2025 to now11
- Senior VP, Finance and PAODavid Foehr Oct 10, 2024 to now12
- Chief Business OfficerJoshua Copp Oct 10, 2024 to Oct 10, 202413
- Chief Technology OfficerRaymond Woo Oct 10, 2024 to now14
- Board memberSharon O'Keefe Jul 30, 2026 to now15
- Board memberThomas A. West Jul 30, 2026 to now16
- Board memberErica J. Rogers Sep 19, 2025 to now17
- Board memberBakker Juliet Tammenoms Oct 10, 2024 to now18
- Board memberJosef Parvizi Oct 10, 2024 to now19
- Board memberLucian Iancovici Oct 10, 2024 to Oct 10, 202420
- Board memberRebecca B. Robertson Oct 10, 2024 to now21
- Board memberWilliam W. Burke Oct 10, 2024 to now22
- Board memberXingjuan Chao Oct 10, 2024 to now9
Named in SEC Form D filings
People the company listed in its private-offering notices.
Timeline
- Aug 10, 20268-K Results of operations24
- Jul 30, 20268-K Executive or director change25
- Jun 2, 20268-K Shareholder vote26
- May 11, 20268-K Results of operations27
- Feb 24, 20268-K Results of operations28
- Jan 5, 20268-K Other events29
- Jan 2, 20268-K Executive or director change30
- Dec 12, 20258-K Entered a material agreement31
- Dec 9, 20258-K Other events32
- Nov 24, 20258-K Other events33
- Nov 4, 20258-K Results of operations34
- Sep 24, 20258-K Entered a material agreement35
- Oct 10, 2024New chief executive Xingjuan Chao becomes CEO9
- Aug 29, 2014Founded Ceribell, Inc. is founded2
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.37) a share, on Nov 4, 2025.36
When it reported results
- Aug 10, 2026Reported quarterly or annual results24
- May 11, 2026Reported quarterly or annual results27
- Feb 24, 2026Reported quarterly or annual results28
- Nov 4, 2025Reported quarterly or annual results34
- Aug 5, 2025Reported quarterly or annual results37
- May 8, 2025Reported quarterly or annual results38
- Feb 25, 2025Reported quarterly or annual results39
- Nov 12, 2024Reported quarterly or annual results40
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
301 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 24 major events, 132 insider forms, 17 large holders, 1 private raises, 119 other. The latest 20:
- Oct 2, 20264 EDGAR
- Oct 1, 2026144 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 8, 2026144 EDGAR
- Sep 8, 2026144 EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Aug 25, 20264 EDGAR
- Aug 25, 20264 EDGAR
- Aug 25, 20264 EDGAR
- Aug 25, 20264 EDGAR
- Aug 25, 20264 EDGAR
- Aug 24, 2026144 EDGAR
The 301 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
84 open-market trades by officers, directors and large owners since October 2021: 2 buys and 82 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Chao XingjuanPresident and CEO | Sale | 20,846 | $25.03 | $521.8K | Form 4 |
| Sep 15, 2026 | Blumberg ScottChief Financial Officer | Sale | 846 | $25.00 | $21.1K | Form 4 |
| Sep 8, 2026 | Foehr DavidSenior VP, Finance and PAO | Sale | 9,255 | $24.25 | $224.5K | Form 4 |
| Sep 8, 2026 | Woo RaymondChief Technology Officer | Sale | 4,887 | $24.33 | $118.9K | Form 4 |
| Sep 2, 2026 | Chao XingjuanPresident and CEO | Sale | 39,540 | $24.61 | $973.1K | Form 4 |
| Sep 2, 2026 | Blumberg ScottChief Financial Officer | Sale | 652 | $25.00 | $16.3K | Form 4 |
| Aug 24, 2026 | Foehr DavidSenior VP, Finance and PAO | Sale | 859 | $23.95 | $20.6K | Form 4 |
| Aug 21, 2026 | Manni Joseph S.Chief Revenue Officer | Sale | 1,361 | $24.02 | $32.7K | Form 4 |
| Aug 21, 2026 | Foehr DavidSenior VP, Finance and PAO | Sale | 993 | $24.02 | $23.9K | Form 4 |
| Aug 21, 2026 | Woo RaymondChief Technology Officer | Sale | 1,979 | $24.02 | $47.5K | Form 4 |
| Aug 21, 2026 | Blumberg ScottChief Financial Officer | Sale | 1,521 | $24.02 | $36.5K | Form 4 |
| Aug 21, 2026 | Chao XingjuanPresident and CEO | Sale | 6,068 | $24.02 | $145.8K | Form 4 |
| Aug 19, 2026 | Blumberg ScottChief Financial Officer | Sale | 33,512 | $25.03 | $838.8K | Form 4 |
| Aug 19, 2026 | Chao XingjuanPresident and CEO | Sale | 31,415 | $25.03 | $786.3K | Form 4 |
| Aug 18, 2026 | Blumberg ScottChief Financial Officer | Sale | 990 | $25.00 | $24.8K | Form 4 |
| Aug 18, 2026 | Chao XingjuanPresident and CEO | Sale | 2,199 | $25.00 | $55.0K | Form 4 |
| Aug 13, 2026 | Taylor Joseph MichaelDirector | Sale | 13,095 | $23.40 | $306.4K | Form 4 |
| Aug 3, 2026 | Chao XingjuanPresident and CEO | Sale | 39,000 | $18.32 | $714.5K | Form 4 |
| Jul 7, 2026 | Chao XingjuanPresident and CEO | Sale | 39,000 | $19.90 | $776.1K | Form 4 |
| Jun 30, 2026 | BURKE WILLIAM WDirector | Sale | 2,207 | $19.84 | $43.8K | Form 4 |
All 84 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- TPG GP A, LLCSCHEDULE 13G/A, 2 filings Feb 13, 2025 to Aug 14, 202641
- FMR LLCSCHEDULE 13G/A, 5 filings Nov 7, 2024 to Aug 6, 202642
- BlackRockSCHEDULE 13G, 1 filing Jul 27, 202643
- Global Value Investment Portfolio Management Pte LtdSCHEDULE 13G/A, 2 filings Feb 20, 2025 to May 14, 202644
- Xingjuan ChaoSCHEDULE 13G/A, 2 filings Feb 12, 2025 to May 12, 202645
- ABG Management Ltd.SCHEDULE 13G/A, 2 filings May 2, 2025 to Dec 11, 202546
- Red Tree GP, LLCSCHEDULE 13G, 1 filing Feb 14, 202547
- Josef ParviziSCHEDULE 13G, 1 filing Feb 12, 202548
- Longitude Capital Partners IV, LLCSC 13D, 1 filing Oct 22, 202449
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Xingjuan (Jane) ChaoPh.D. | $639.0K | $4.6M50 | |
| 2025 | Scott Blumberg | 44 | $430.0K | $1.8M50 |
| 2025 | Raymond WooPh.D. | $418.5K | $1.8M50 | |
| 2024 | President, ChiefExecutive Officer, and Co-Founder | $494.5K | $1.8M50 | |
| 2024 | Chief Financial Officer | $348.9K | $1.0M50 | |
| 2024 | Chief Technology Officer | $337.5K | $703.9K50 |
Money raised
Private offerings the company reported to the SEC on Form D.
- Apr 22, 2021Raised $102.5 million in a private offering of equity Form D: 17 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 5,691,393 | $110.7M | 0.0% | +840,962 |
| Tpg Gp A, LLC | 3,761,154 | $73.2M | 1.5% | −206,268 |
| Red Tree Management, LLC | 2,205,661 | $42.9M | 29.1% | No change |
| BlackRock, Inc. | 1,936,093 | $37.7M | 0.0% | +122,938 |
| Vanguard Capital Management LLC | 1,130,346 | $22.0M | 0.0% | −6,786 |
| KCM Capital Inc | 1,125,000 | $21.9M | 3.6% | −275,000 |
| Federated Hermes, Inc. | 939,600 | $18.3M | 0.0% | +136 |
| Franklin Resources Inc | 918,349 | $17.9M | 0.0% | +108,835 |
| Adage Capital Partners Gp, L.l.c. | 900,000 | $17.5M | 0.0% | +143,249 |
| Bank of New York Mellon Corp | 896,488 | $17.4M | 0.0% | −264,279 |
| TimesSquare Capital Management, LLC | 780,552 | $15.2M | 0.2% | +64,084 |
| Millennium Management LLC | 727,225 | $14.1M | 0.0% | +175,204 |
| Geode Capital Management, LLC | 668,134 | $13.0M | 0.0% | +56,157 |
| Royce & Associates LP | 605,010 | $11.8M | 0.1% | +89,290 |
| State Street Corp | 547,035 | $10.6M | 0.0% | +21,603 |
| Silvercrest Asset Management Group LLC | 468,806 | $9.1M | 0.1% | −20,936 |
| Massachusetts Financial Services Co /ma/ | 389,675 | $7.6M | 0.0% | −118,815 |
| Redmile Group, LLC | 386,786 | $7.5M | 0.5% | No change |
| Jpmorgan Chase & Co | 345,152 | $6.9M | 0.0% | +57,946 |
| Yu Fan | 342,398 | $6.7M | 6.2% | −207,050 |
| Peregrine Capital Management LLC | 331,413 | $6.4M | 0.2% | −16,806 |
| Creek Drive Management Group LLC | 300,881 | $5.9M | 3.6% | −22,119 |
| Morgan Stanley | 285,661 | $5.6M | 0.0% | +54,743 |
| Goldman Sachs Group Inc | 280,309 | $5.5M | 0.0% | −130,722 |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 275,328 | $5.4M | 62.6% | −166,492 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Ceribell, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCeribell, Inc.1
- CIK0001861107
- Employer ID (EIN)47-17854524
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address360 N. Pastoria Avenue, Sunnyvale, CA 940851
- Phone(800) 436-08261
- Shares outstanding38,378,101 as of Aug 6, 20268
- Public float$417.2M as of Jun 30, 20254
- AuditorPricewaterhouseCoopers LLP, San Jose, California PCAOB ID 238; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMay 7, 20211
- Filings302 in all: 4 (111), 144 (83), 8-K (24), 3 (16), SCHEDULE 13G/A (8), SCHEDULE 13G (7), 10-Q (6), CORRESP (6)1
All 32 form types
4/A (4), UPLOAD (4), DEFA14A (3), S-1/A (3), S-8 (3), 10-K (2), ARS (2), DEF 14A (2), EFFECT (2), SEC STAFF LETTER (2), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), D (1), D/A (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), S-1 (1), S-3 (1), SC 13D (1), SC 13G (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Aug 10, 2026
Proxy statement (DEF 14A) Apr 20, 2026
Latest 8-K (8-K) Aug 10, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, $0.001 par value per share | CBLL | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Ceribell, Inc. names in Item 1A of its 10-K filed Feb 24, 2026: 72 risks under these headings, as written.4
- Business and Industry Risk Factors
- We have a limited operating history and have experienced rapid growth, which may strain our resources and make it difficult to evaluate our business and future prospects. If we are unable to manage our expansion effectively, our business could be materially and adversely affected.
- We have a history of net losses, and we expect to incur additional substantial losses in the foreseeable future.
- We depend on sales from the use of the Ceribell System for our revenue. If we are unable to successfully achieve substantial market acceptance and adoption of the Ceribell System, or any of our future products, or if confidence in our products is diminished, our business, financial condition, results of operations, and prospects would be harmed.
- We operate in a highly competitive industry, and competitive pressures could have a material adverse effect on our business, financial condition, results of operations, and prospects.
- Adapting our manufacturing and production capacities to evolving patterns of demand is expensive, time-consuming, and subject to significant uncertainties. We may not be able to adequately predict emerging customer trends and may be unable to adjust our production and inventory levels in a timely manner.
- Changes in trade policy, tariffs, and our reliance on international manufacturing and supply chain operations expose us to foreign operational and trade risks that may adversely affect our business, results of operations, and financial condition.
- If we cannot innovate at the pace of our competitors, we may not be able to develop or exploit new technologies in time to remain competitive.
- Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information, and personal data.
- Any future sales in international markets will subject us to additional costs and risks that may have a material adverse effect on our business, financial condition, results of operations, and prospects.
- If we fail to attract and retain senior management and other key personnel, our business may be materially and adversely affected.
- If we fail to maintain our culture, our business may be negatively affected.
The other 61 risks
- If we are unable to successfully develop new products and effectively manage their introduction or improve our existing products, our business may be adversely affected.
- Our products are complex to design and manufacture and can contain defects. The production and sale of defective products could adversely affect our business, financial condition, results of operations, and prospects. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit sales of our products.
- The size and expected growth of our addressable market has not been established with precision, and may be smaller than we estimate.
- Alternative technologies or therapies addressing seizure, non-convulsive status epilepticus or other indications we intend to expand into could materially adversely affect our business, financial condition, results of operations, and prospects.
- We may in the future be deemed to manufacture or contract to manufacture products that contain conflict minerals.
- Macroeconomic conditions could materially adversely affect our business, financial condition, results of operations, and prospects.
- Shutdowns of the U.S. federal government could materially adversely affect our business, financial condition, results of operations, and prospects.
- Risk Related to Regulatory Matters
- If adequate reimbursement becomes unavailable for the diagnostic tests using our products, it could diminish our sales or affect our ability to sell the Ceribell System profitably.
- The continued commercialization of our products depends in part on the extent to which governmental authorities and health insurers provide coverage and adequate reimbursement levels. Failure to obtain and maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.
- We are subject to certain federal and state fraud and abuse laws and transparency laws, and any failure to comply could subject us to substantial penalties or other adverse consequences. In addition, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.
- Our employees, consultants and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could have a material adverse effect on our business, financial condition, results of operations, and prospects.
- Our products and operations are subject to extensive government regulation and oversight in the United States, and our failure to comply with applicable requirements could harm our business.
- Failure to maintain marketing authorizations for our products, or to timely obtain necessary marketing authorizations for our future products, may have a material adverse effect on our business, financial condition, results of operations, and prospects.
- Our clinical testing process is complex, lengthy, can be expensive, and carries uncertain outcomes. Future trials and studies by us or others may fail to replicate positive results observed to date.
- Interim, “top-line,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- We are subject to ongoing regulatory review and scrutiny. Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market.
- Our products must be manufactured in accordance with applicable laws and regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations.
- Our products may cause or contribute to adverse medical events which we may be required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, results of operations, and prospects. In addition, the discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA, could have a negative impact on us.
- The misuse or off-label use of our products may result in injuries that harm patients and lead to product liability suits, harm our reputation in the marketplace, or result in costly investigations, fines, or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
- Legislative or regulatory reforms in the United States may make it more difficult and costly for us to manufacture, market, or distribute our products, or to obtain marketing authorizations for any future products.
- We face risks related to obtaining necessary foreign regulatory clearance or approvals.
- Failure to comply with the Foreign Corrupt Practices Act (the “FCPA”), economic and trade sanctions regulations, and similar laws could subject us to penalties and other adverse consequences.
- Risks Related to Our Reliance on Third Parties
- Various factors outside our direct control may negatively impact our manufacturing of the Ceribell System, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
- We depend on a number of manufacturers and suppliers in connection with the manufacture of the Ceribell System, which makes us vulnerable to supply shortages and price fluctuations that could have a material adverse effect on our business, financial condition, results of operations, and prospects.
- We rely on third parties to conduct and support our preclinical studies and clinical trials. These third parties may not properly and successfully carry out their contractual duties or meet expected deadlines, which could harm our ability to obtain marketing authorization of or commercialize future products we develop.
- Data Privacy Risk Factors
- Actual or perceived failures to comply with applicable data privacy and security laws, regulations, standards and other requirements could adversely affect our business, financial condition, results of operations, and prospects.
- We may face risks associated with our use and development of AI and machine learning models.
- Our business and operations may suffer in the event of information technology system failures, cyber attacks, or deficiencies in our cybersecurity.
- Risks Related to Our Intellectual Property
- Our success will depend on our and our licensors’ ability to obtain, maintain, enforce, and protect our intellectual property rights.
- If we fail to identify our patentable inventions or adequately protect our patent rights, the commercial value of our products, services or technologies may be adversely affected and our competitive position may be harmed.
- Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Changes in U.S. or foreign patent laws or their interpretations could diminish the value of our patents in general, thereby impairing our ability to protect our current and future products, services, or technologies, and could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our current or future patents.
- We may not be able to protect our intellectual property rights throughout the world.
- If we cannot successfully enforce our intellectual property rights, the commercial value of our products, services, or technologies may be adversely affected and our competitive position may be harmed.
- We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, and unsuccessful, and could interfere with our ability to develop, manufacture, commercialize, import, or otherwise use our products, services, or technologies.
- We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights.
- We depend on certain intellectual property rights that are licensed to us. We may be unsuccessful in licensing or acquiring intellectual property rights from third parties that may be necessary to develop, manufacture, commercialize, import, or use our current and/or future products, services, or technologies.
- If we are unable to protect the disclosure and use of our confidential information and trade secrets, the value of our products, services, and technologies and our business and competitive position could be harmed.
- If our trademarks and trade names are not adequately protected, we may not be able to build brand name recognition in our markets of interest and our competitive position may be harmed.
- Our products contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products, affect our ability to protect our proprietary information, and subject us to possible litigation.
- We are subject to certain manufacturing restrictions related to licensed intellectual property rights that were developed with the financial assistance of United States government grants.
- Risks Relating to Financial and Accounting Matters
- Our ability to use our net operating loss carryforwards and other tax attributes may be limited due to certain provisions of the Internal Revenue Code or state tax law.
- Our effective tax rate may vary significantly from period to period.
- Changes in tax laws or tax rulings could adversely affect our effective tax rates, results of operations and financial condition.
- Our venture loan and security agreement contains restrictions that limit our flexibility in operating our business.
- Our cash deposits with financial institutions exceed insured limits.
- Risks Relating to Ownership of Our Common Stock
- We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.
- We incur significant costs as a result of operating as a public company. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would seriously harm our business.
- We do not intend to pay dividends in the foreseeable future. As a result, your ability to achieve a return on your investment will depend on appreciation in the market price of our common stock.
- If our operating and financial performance in any given period does not meet the guidance provided to the public or the expectations of investment analysts, the market price of our common stock may decline.
- Future securities issuances could result in significant dilution to our stockholders and impair the market price of our common stock.
- We may require additional capital to support business growth, and this capital might not be available on terms favorable to us, or at all, and may dilute existing stockholders’ ownership of our common stock.
- Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.
- Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
- Claims for indemnification by our directors, officers, and other employees or agents may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
- Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
- The market price of our common stock may be volatile, which could cause the value of your investment to decline.
- If securities or industry analysts do not continue to publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
- General Risk Factors
- If we engage in acquisitions or strategic partnerships, it may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
- We or the third parties we depend on may be adversely affected by natural disasters and other catastrophic events, and our business continuity and disaster recovery plans may not adequately protect us from a serious natural disaster or other catastrophic event. Any
Legal proceedings
On July 7, 2025, we filed patent infringement complaints against Natus Medical Incorporated and related subsidiaries (“Natus”) with the U.S. International Trade Commission (“USITC”) and the U.S. District Court for the District of Delaware (the “District Court”), alleging that Natus is infringing on six patents owned by us related to important features of the Ceribell EEG headband and electrode design through Natus’s making, using, selling, offering for sale in the United States, and/or importing into the United States, of rapid point-of-care EEG monitoring products (the “Natus Products”), and that Natus is engaging in unfair competition. We have requested that the USITC investigate these claims and issue an exclusion order to bar the importation of any infringing Natus Products into the United States. We have also requested in the District Court a permanent injunction against the Natus Products and an award of damages sufficient to compensate us for the alleged infringement, as well as other costs and expenses in this action. On August 6, 2025, the USITC instituted an investigation of these claims pursuant to Section 337 of the Tariff Act of 1930 and on August 12, 2025, the District Court stayed the pending patent infringement action until the final determination of the USITC investigation. A federal government shutdown may cause delays in the progress of the USITC investigation and related proceedings until normal operations resume.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCeribell, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARCeribell, Inc. filings on SEC EDGAR
- 4
- 5SEC EDGARCeribell, Inc. 10-K for fiscal 2025
- 6SEC EDGARCeribell, Inc. 10-K for fiscal 2023
- 7SEC EDGARCeribell, Inc. 10-Q for fiscal 2026
- 8SEC EDGARCeribell, Inc. 10-Q for fiscal 2026
- 9
- 10
- 11
- 12
- 13SEC EDGARJoshua Copp, Chief Business Officer
- 14
- 15SEC EDGARSharon O'Keefe, Board member
- 16SEC EDGARThomas A. West, Board member
- 17SEC EDGARErica J. Rogers, Board member
- 18
- 19SEC EDGARJosef Parvizi, Board member
- 20SEC EDGARLucian Iancovici, Board member
- 21SEC EDGARRebecca B. Robertson, Board member
- 22SEC EDGARWilliam W. Burke, Board member
- 23
- 24SEC EDGARResults of operations
- 25SEC EDGARExecutive or director change
- 26SEC EDGARShareholder vote
- 27SEC EDGARResults of operations
- 28SEC EDGARResults of operations
- 29SEC EDGAROther events
- 30SEC EDGARExecutive or director change
- 31SEC EDGAREntered a material agreement
- 32SEC EDGAROther events
- 33SEC EDGAROther events
- 34SEC EDGARResults of operations
- 35SEC EDGAREntered a material agreement
- 36NasdaqNasdaq calendar
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50